Fibroblast News and Research

RSS

Fibroblasts are connective tissue cells which secrete an extracellular matrix rich in collagen and other macromolecules.

FGF21 compound in breast milk plays key role in neonatal nutrient absorption, intestinal function

A compound found in breast milk, named fibroblast growth factor 21 (FGF21), plays a key role in neonatal nutrient absorption and intestinal function. FGF21 also contributes to improve newborn growth and metabolic profile.

11 Sep 2015

New study reveals effect of diabetes drug on bone health, benefit of exercise in mice

Inside our bones there is fat. Diabetes increases the amount of this marrow fat. And now a study from the UNC School of Medicine shows how some diabetes drugs substantially increase bone fat and thus the risk of bone fractures.

9 Sep 2015

Scientists reveal how a common gene mutation in ALS and FTD disrupts normal cell function

Researchers have determined how the most common gene mutation in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) disrupts normal cell function, providing insight likely to advance efforts to develop targeted therapies for these brain diseases.

27 Aug 2015

FGF protein may play key role in breast and prostate cancer, shows research

Simply put, cancer is caused by mutations to genes within a cell that lead to abnormal cell growth. Finding out what causes that genetic mutation has been the holy grail of medical science for decades.

13 Aug 2015

In vitro testing provides proof of concept for osteopathic manipulative therapy

In vitro studies of the cellular effects of modeled osteopathic manipulative therapy (OMT) provide proof of concept for the manual techniques practiced by doctors of osteopathic medicine (DOs), according to researchers from the University of Arizona College of Medicine - Phoenix.

5 Aug 2015

RepliCel obtains two important approvals to conduct RCS-01 phase 1 human clinical trial

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced it has received two important approvals required to conduct its RCS-01 phase 1 human clinical trial.

21 Jul 2015

Updated guidelines released for treatment of idiopathic pulmonary fibrosis

Updated guidelines on the treatment of idiopathic pulmonary fibrosis (IPF) have been released by an international group of leading respiratory societies, The new guidelines, issued by the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association, were published in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

15 Jul 2015

FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

Blueprint Medicines today announced that the U.S. Food and Drug Administration accepted the Company's Investigational New Drug (IND) applications to begin Phase 1 clinical trials for its two lead drug candidates: BLU-554 for the treatment of advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma, and BLU-285 for unresectable, treatment-resistant gastrointestinal stromal tumor (GIST).

13 Jul 2015

Globavir agrees to exclusively license novel oncology compound to Sorrento Therapeutics

Globavir Biosciences, Inc., a specialty biotechnology company developing small molecule drugs to treat cancer and infectious diseases, and Sorrento Therapeutics, Inc., an oncology company developing new treatments for cancer and associated pain, announced today that the companies have entered into an agreement under which Globavir exclusively licensed its novel oncology compound, BC001, to Sorrento Therapeutics.

9 Jul 2015

Researchers compare effectiveness of two stem cell types in treating retinal degeneration

By growing two types of stem cells in a "3-D culture" and measuring their ability to produce retinal cells, a team lead by St. Jude Children's Research Hospital researchers has found one cell type to be better at producing retinal cells.

3 Jul 2015

First participant enrolled in RepliCel's RCT-01 Phase 1/2 clinical trial for treatment of chronic tendinosis

RepliCel Life Sciences Inc., a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that the first participant in its Phase 1/2 clinical trial of RCT-01, being tested for the treatment of chronic unilateral Achilles tendinosis, has been enrolled and their tissue biopsy sent for processing prior to intra-tendon ultrasound-guided injections.

30 Jun 2015

Researchers explore the science of exosomes in heart repair

A little more than a decade ago, researchers discovered that all cells secrete tiny communications modules jammed with an entire work crew of messages for other cells. Today, a team of researchers, led by stem cell researcher Raj Kishore, PhD, Director of the Stem Cell Therapy Program at the Center for Translational Medicine at Temple University School of Medicine, is harnessing the communications vesicles excreted by stem cells and using them to induce the damaged heart to repair itself.

19 Jun 2015

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Eisai Inc. announced today results from an investigational Phase 2 trial which showed that lenvatinib, when used in combination with everolimus, significantly extended progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) versus everolimus alone.

1 Jun 2015

Process of aging could be delayed in human cell lines

Can the process of aging be delayed or even reversed? Research led by specially appointed Professor Jun-Ichi Hayashi from the University of Tsukuba in Japan has shown that, in human cell lines at least, it can. They also found that the regulation of two genes involved with the production of glycine, the smallest and simplest amino acid, is partly responsible for some of the characteristics of aging.

1 Jun 2015

Two grants to bolster research on why ovarian cancer is resistant to chemotherapy

Determining which strains of cancer will eventually become resistant to chemotherapy could be key in figuring out more effective and targeted forms of treatment. Finding the genes responsible for chemo-resistance is what Jeremy Chien, Ph.D., member of the Cancer Biology Program at The University of Kansas Cancer Center, is looking to do with an innovative system that draws inspiration from the early days of cancer gene research.

1 Jun 2015

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Amgen today announced pooled data from two pivotal Phase 3, global, randomized, placebo-controlled trials evaluating AMG 416, a novel calcimimetic, for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD) receiving hemodialysis.

29 May 2015

Novel drug target identified for treating rheumatoid arthritis

Researchers at the La Jolla Institute for Allergy and Immunology, in collaboration with colleagues the University of California, San Diego, identified a novel drug target for the treatment of rheumatoid arthritis that focuses on the cells that are directly responsible for the cartilage damage in affected joints.

21 May 2015

Overview of Blueprint Medicines' kinase drug discovery strategy published in JCI

Blueprint Medicines today announced that the Journal of Clinical Investigation published an overview of the Company's kinase drug discovery and development strategy. The publication underscores Blueprint Medicines' focus on identifying novel genomically defined disease drivers and the use of novel chemistry from its proprietary compound library to craft highly selective kinase inhibitors for new and difficult-to-drug kinase targets.

11 May 2015

Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Blueprint Medicines today announced new preclinical data demonstrating that BLU-554, a selective and potent inhibitor of fibroblast growth factor receptor 4 (FGFR4), has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signaling.

25 Apr 2015

Study identifies BLU-554 as potential treatment option for HCC patients

Findings were presented today at The International Liver CongressTM 2015 on a novel therapeutic candidate for a genomically defined subset of hepatocellular carcinoma (HCC) patients with an aberrant fibroblast growth factor receptor 4 (FGFR4) pathway.

25 Apr 2015

Fibroblast News and Research

Further Reading

FGF21 compound in breast milk plays key role in neonatal nutrient absorption, intestinal function

New study reveals effect of diabetes drug on bone health, benefit of exercise in mice

Scientists reveal how a common gene mutation in ALS and FTD disrupts normal cell function

FGF protein may play key role in breast and prostate cancer, shows research

In vitro testing provides proof of concept for osteopathic manipulative therapy

RepliCel obtains two important approvals to conduct RCS-01 phase 1 human clinical trial

Updated guidelines released for treatment of idiopathic pulmonary fibrosis

FDA accepts Blueprint Medicines' IND applications to start Phase 1 clinical trials for two drug candidates

Globavir agrees to exclusively license novel oncology compound to Sorrento Therapeutics

Researchers compare effectiveness of two stem cell types in treating retinal degeneration

First participant enrolled in RepliCel's RCT-01 Phase 1/2 clinical trial for treatment of chronic tendinosis

Researchers explore the science of exosomes in heart repair

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Process of aging could be delayed in human cell lines

Two grants to bolster research on why ovarian cancer is resistant to chemotherapy

Amgen announces AMG 416 Phase 3 results for treatment of secondary hyperparathyroidism in CKD patients

Novel drug target identified for treating rheumatoid arthritis

Overview of Blueprint Medicines' kinase drug discovery strategy published in JCI

Therapeutic candidate BLU-554 has significant anti-tumor activity in HCC models

Study identifies BLU-554 as potential treatment option for HCC patients

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News